Reappraisal of 2003 NKF-K/DOQI guidelines for management of hyperparathyroidism in chronic kidney disease patients

被引：0
作者：
Matthieu Monge
Irina Shahapuni
Roxana Oprisiu
Najeh El Esper
Philippe Morinière
Ziad Massy
Gabriel Choukroun
Albert Fournier
机构：
[1] Department of Nephrology Internal Medicine Intensive Care,
[2] all in the Department of Nephrology Internal Medicine,undefined
[3] nephrology consultant in the Geriatrics Department,undefined
[4] nephrology consultant and Professor of Pharmacology and Director of INSERM-ERI-12,undefined
[5] all at Amiens University Hospital,undefined
[6] Jules Verne University of Picardy,undefined
来源：
Nature Clinical Practice Nephrology | 2006年 / 2卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Since the latest K/DOQI guidelines were formulated, new data on drugs such as lanthanum carbonate and calcimimetics have become available. In light of this new information, Matthieu Monge and colleagues believe that current practice can be updated. In this Review, the authors outline their recommendations regarding drug selection, dosing regimens, and monitoring of hyperparathyroidism in dialysis patients.
引用
收藏
页码：326 / 336
页数：10
相关论文
共 70 条
[1]  
Shahapuni I(2005)How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients? Semin Dial 18 226-238
[2]  
Block GA(2004)Mineral metabolism, mortality, and morbidity in maintenance hemodialysis J Am Soc Nephrol 15 2208-2218
[3]  
Fournier A(2001)Optimal range of plasma concentration of true 1-84 parathyroid hormone in patients on maintenance dialysis J Clin Endocrinol Metab 86 1840-1842
[4]  
Fournier AE(1971)Etiology of hyperparathyroidism and bone disease during chronic hemodialysis: I. Association of bone disease with potentially etiologic factors J Clin Invest 50 592-598
[5]  
Fournier AE(1971)Etiology of hyperparathyroidism and bone disease during chronic hemodialysis: II. Factors affecting serum immunoreactive parathyroid hormone J Clin Invest 50 599-605
[6]  
Touam M(2005)High dialysate calcium may improve the efficacy of calcimimetic treatment in hemodialysis patients with severe secondary hyperparathyroidism Kidney Int 67 2065-1525
[7]  
Block GA(2004)Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis N Engl J Med 350 1516-2177
[8]  
Ghazali A(1999)Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol? Kidney Int 55 2169-588
[9]  
Sadek T(2003)Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study Nephrol Dial Transplant 18 582-294
[10]  
Mucsi I(2005)Serum 25(OH)-vitamin D levels and bone metabolism in patients on maintenance hemodialysis Clin Nephrol 64 288-766
1234567